Focus Partners Wealth raised its position in Liquidia Co. (NASDAQ:LQDA - Free Report) by 20.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 90,500 shares of the company's stock after buying an additional 15,500 shares during the period. Focus Partners Wealth owned 0.11% of Liquidia worth $1,064,000 as of its most recent filing with the SEC.
Several other hedge funds have also recently modified their holdings of the company. Steward Partners Investment Advisory LLC purchased a new stake in Liquidia during the fourth quarter worth about $59,000. Summit Investment Advisors Inc. increased its stake in shares of Liquidia by 35.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company's stock worth $78,000 after purchasing an additional 1,719 shares during the last quarter. D. E. Shaw & Co. Inc. bought a new stake in shares of Liquidia in the 4th quarter worth approximately $142,000. EntryPoint Capital LLC purchased a new position in Liquidia in the fourth quarter valued at approximately $154,000. Finally, Bayesian Capital Management LP bought a new position in Liquidia during the fourth quarter valued at $163,000. Institutional investors own 64.54% of the company's stock.
Insider Activity
In other news, General Counsel Russell Schundler sold 5,964 shares of the firm's stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $13.57, for a total value of $80,931.48. Following the transaction, the general counsel now owns 570,301 shares in the company, valued at approximately $7,738,984.57. This trade represents a 1.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Roger Jeffs sold 14,130 shares of the company's stock in a transaction on Monday, April 14th. The shares were sold at an average price of $13.57, for a total transaction of $191,744.10. Following the sale, the chief executive officer now owns 1,006,420 shares of the company's stock, valued at $13,657,119.40. This represents a 1.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 33,138 shares of company stock valued at $450,233. 26.50% of the stock is currently owned by insiders.
Analyst Upgrades and Downgrades
LQDA has been the topic of several recent analyst reports. Scotiabank reiterated an "outperform" rating on shares of Liquidia in a research note on Monday, May 5th. Raymond James lifted their price objective on Liquidia from $27.00 to $29.00 and gave the company a "strong-buy" rating in a research note on Friday, May 9th. Oppenheimer lowered Liquidia from a "market perform" rating to an "underperform" rating and set a $13.00 target price on the stock. in a research note on Monday. HC Wainwright reaffirmed a "buy" rating and issued a $29.00 price target on shares of Liquidia in a report on Monday, May 12th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $25.00 price target on shares of Liquidia in a research report on Wednesday. One analyst has rated the stock with a sell rating, six have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $25.56.
Read Our Latest Research Report on Liquidia
Liquidia Stock Performance
LQDA traded down $0.36 during midday trading on Wednesday, hitting $16.66. The stock had a trading volume of 1,759,797 shares, compared to its average volume of 1,039,688. The company has a market cap of $1.42 billion, a P/E ratio of -10.22 and a beta of 0.24. Liquidia Co. has a 1 year low of $8.26 and a 1 year high of $19.41. The business has a fifty day moving average of $14.67 and a 200 day moving average of $13.48.
Liquidia (NASDAQ:LQDA - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.03). The business had revenue of $3.12 million during the quarter, compared to analysts' expectations of $3.23 million. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. On average, equities research analysts anticipate that Liquidia Co. will post -1.51 earnings per share for the current year.
About Liquidia
(
Free Report)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Further Reading
Before you consider Liquidia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Liquidia wasn't on the list.
While Liquidia currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
